Background
C-1011 is the result of a neurochemical development contract between the United States Military and Spearhead. The chemical has recently been developed into an aerosol drug that is administered through an oral inhaler. C-1011 is currently in the midst of classified clinical testing.
C-1011 has been found to mentally dissociate a person's actions from their awareness of those actions. Not unlike hypnosis, C-1011 creates a mental state in which the individual becomes fully engrossed in what they are doing to the point that they do not have to think about what they are doing; instead they just do it. The current focus of the study is to assess the applicable uses of the drug as a combat enhancement.
Bios
Subject 17 - Owen Miller
Age - 45
Experience - Army (Retired)
Qualifier - Miller was blacklisted from the Army on account of being a whistleblower. Subject exhibits strong tendencies towards “right” and “wrong” and is not afraid to report illicit behavior.
Subject 18 - Kyle Jackson
Age - 19
Experience - Marine (Enlisted, Pvt.)
Qualifier - Severe leg injury from a getting caught in a lift. Underwent extensive surgery and physical therapy, during which the subject exhibited extremely high resistance to anesthetics.
Operation #8
Operation Coordinator - William Wright
Clinical Evaluation - Dr. Andrew Aaronson
Clinical Trial - C-1011
Enhancement - beta-adrenoceptor
Participants - Owen Miller, Kyle Jackson
Location - Spearhead (Mexico)
Objective - Rescue & extract
Result - Successful memory reconsolidation
Triggers - Imagery, Audio (augmented)
C-1011 is the result of a neurochemical development contract between the United States Military and Spearhead. The chemical has recently been developed into an aerosol drug that is administered through an oral inhaler. C-1011 is currently in the midst of classified clinical testing.
C-1011 has been found to mentally dissociate a person's actions from their awareness of those actions. Not unlike hypnosis, C-1011 creates a mental state in which the individual becomes fully engrossed in what they are doing to the point that they do not have to think about what they are doing; instead they just do it. The current focus of the study is to assess the applicable uses of the drug as a combat enhancement.
Bios
Subject 17 - Owen Miller
Age - 45
Experience - Army (Retired)
Qualifier - Miller was blacklisted from the Army on account of being a whistleblower. Subject exhibits strong tendencies towards “right” and “wrong” and is not afraid to report illicit behavior.
Subject 18 - Kyle Jackson
Age - 19
Experience - Marine (Enlisted, Pvt.)
Qualifier - Severe leg injury from a getting caught in a lift. Underwent extensive surgery and physical therapy, during which the subject exhibited extremely high resistance to anesthetics.
Operation #8
Operation Coordinator - William Wright
Clinical Evaluation - Dr. Andrew Aaronson
Clinical Trial - C-1011
Enhancement - beta-adrenoceptor
Participants - Owen Miller, Kyle Jackson
Location - Spearhead (Mexico)
Objective - Rescue & extract
Result - Successful memory reconsolidation
Triggers - Imagery, Audio (augmented)
No comments:
Post a Comment